Livzon Pharmaceutical Group Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Livzon Pharmaceutical Group (SZSE:000513) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥3.04b (down 7.2% from 2Q 2023).
- Net income: CN¥563.1m (up 1.9% from 2Q 2023).
- Profit margin: 19% (up from 17% in 2Q 2023). The increase in margin was driven by lower expenses.
- EPS: CN¥0.62 (up from CN¥0.60 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Livzon Pharmaceutical Group EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) exceeded analyst estimates by 13%.
Looking ahead, revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are down 3.8% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Livzon Pharmaceutical Group that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:000513
Livzon Pharmaceutical Group
Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China.
Undervalued with excellent balance sheet and pays a dividend.